Clinical Trials in Los Angeles

Showing 641-660 of 12,794 trials

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.

Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more

Atavistik Bio, Inc134 participantsStarted Jul 2025

Los Angeles, California, United States • Lake Mary, Florida, United States • Boston, Massachusetts, United States +5 more locations

RECRUITINGPhase 1< 1 mile

Actinium Therapy for Late-stage Aggressive Sarcomas

NCT07156565

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years

Advanced Soft Tissue Sarcoma

Ratio Therapeutics, Inc.30 participantsStarted Nov 2025

Los Angeles, California, United States • Rochester, Minnesota, United States • New York, New York, United States +3 more locations

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Actinium Therapy for Late-stage Aggressive Sarcomas

Find Trials by Condition in Los Angeles

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Donidalorsen Treatment in Children With Hereditary Angioedema

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Empathic Communication Skills (ECS) Training

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

ELEVATE High-Risk PCI Pivotal Study

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma